Rapt Therapeutics Stock In The News

RAPT Stock  USD 1.17  0.01  0.85%   
Our overall analysis of RAPT Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards RAPT Therapeutics. The specific impact of RAPT Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of RAPT Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using RAPT Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out RAPT Therapeutics Backtesting and RAPT Therapeutics Hype Analysis.
For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.

RAPT Therapeutics Today Top News and Investor Outlook

Yahoo News
RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now
https://finance.yahoo.com/news/rapt-therapeutics-inc-rapt-worst-115718002.html
 Neutral
Yahoo News
RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability
https://finance.yahoo.com/news/rapt-therapeutics-inc-rapt-stock-153441333.html
 Neutral
Yahoo News
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
https://finance.yahoo.com/news/rapt-therapeutics-present-42nd-annual-130000711.html
 Neutral
Macroaxis News: globenewswire.com
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
https://www.globenewswire.com/news-release/2023/11/27/2786122/0/en/RAPT-Therapeutics-Announces-Publication-of-Phase-1a-1b-Clinical-Trial-of-Zelnecirnon-RPT193-to-Treat-Atopic-Dermatitis-in-Allergy.html
 Neutral
Yahoo News
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
https://finance.yahoo.com/news/rapt-therapeutics-announces-publication-phase-130000575.html
 Neutral
Yahoo News
RAPT Therapeutics Inc Reports Increased R&D Expenses Amid Progress in Clinical Trials
https://finance.yahoo.com/news/rapt-therapeutics-inc-reports-increased-004154291.html
 Bullish
Macroaxis News: globenewswire.com
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/11/13/2779017/0/en/RAPT-Therapeutics-Reports-Third-Quarter-2023-Financial-Results.html
 Neutral
Yahoo News
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
https://finance.yahoo.com/news/rapt-therapeutics-reports-third-quarter-130000967.html
 Neutral
Macroaxis News: globenewswire.com
RAPT Therapeutics Announces Positive Dat...
https://www.globenewswire.com/news-release/2023/11/03/2773329/0/en/RAPT-Therapeutics-Announces-Positive-Data-Including-Objective-Response-Rates-and-Progression-Free-Survival-from-its-Phase-2-Trial-of-FLX475-in-Combination-with-a-Checkpoint-Inhibit.html
 Neutral
Yahoo News
RAPT Therapeutics Announces Positive Dat...
https://finance.yahoo.com/news/rapt-therapeutics-announces-positive-data-160000328.html
 Neutral

RAPT Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide RAPT and other traded companies coverage with news coverage. We help investors stay connected with RAPT headlines for the 31st of January to make an informed investment decision based on correlating the impacts of news items on RAPT Stock performance. Please note that trading solely based on the RAPT Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
RAPT Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help RAPT Therapeutics investors visualize upcoming and past events in order to time the market based on RAPT Therapeutics noise-free hype analysis.
RAPT Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the RAPT earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about RAPT Therapeutics that are available to investors today. That information is available publicly through RAPT media outlets and privately through word of mouth or via RAPT internal channels. However, regardless of the origin, that massive amount of RAPT data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of RAPT Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of RAPT Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to RAPT Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive RAPT Therapeutics alpha.

RAPT Largest EPS Surprises

Earnings surprises can significantly impact RAPT Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-03-11
2020-12-31-0.59-0.520.0711 
2020-08-13
2020-06-30-0.58-0.510.0712 
2023-05-11
2023-03-31-0.68-0.76-0.0811 
2024-11-11
2024-09-30-0.56-0.47380.086215 
2023-08-11
2023-06-30-0.78-0.660.1215 
2022-08-11
2022-06-30-0.75-0.620.1317 
View All Earnings Estimates

RAPT Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to RAPT Therapeutics Stock. Current markets are strongly bullish. About 75% of major world exchanges and indexes are currently up. See today's market update for more information.
seekingalpha News
21st of January 2025
RAPT Therapeutics files to sell 176.45M shares of common stock for holders
at seekingalpha.com 
Google News at Macroaxis
7th of January 2025
RAPT Therapeutics Announces Leadership Changes and Realignment - MSN
at news.google.com 
news
27th of December 2024
Insider Trading
at talkmarkets.com 
Macroaxis News: globenewswire.com
23rd of December 2024
RAPT Therapeutics Announces 150 Million Private Placement
at globenewswire.com 
Google News at Macroaxis
6th of December 2024
RAPT Therapeutics stock plunges to 52-week low of 1 - Investing.com
at news.google.com 
news
18th of November 2024
RAPT Therapeutics Analysts Recent Ratings Changes
at thelincolnianonline.com 
news
15th of November 2024
Acquisition by Dirk Brockstedt of 20000 shares of RAPT Therapeutics at 1.57 subject to Rul...
at thelincolnianonline.com 
Macroaxis News: globenewswire.com
12th of November 2024
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
at globenewswire.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards RAPT Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, RAPT Therapeutics' short interest history, or implied volatility extrapolated from RAPT Therapeutics options trading.

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.